# FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC

Source: https://onco.cc/trials/nct07729605/  
OnCo record `nct07729605` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Sun Yat-sen University, not yet recruiting.

## Summary

FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC is a phase 3, randomised interventional study registered as NCT07729605 by Sun Yat-sen University, with a registry enrolment figure of 270 participants, started 2026-07-30 and due to reach its primary completion in 2028-12-30. Interventions recorded: FOLFIRI + bevacizumab + QL1706; FOLFIRI + bevacizumab. Conditions listed: Colorectal Cancer Metastatic; Microsatellite Stable (MSS) Colorectal Cancer (CRC). Primary outcome: Progression-free survival (PFS). Colorectal eligibility wording from the registry: "Histologically confirmed metastatic colorectal adenocarcinoma with pMMR/MSS status". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: FIRBIT
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07729605
- Phase: 3
- Setting: FOLFIRI Plus Bevacizuamb With or Without Iparomlimab and Tuvonralimab as Second-Line Treatment for Metastatic Colorectal Cancer: A Randomized Controlled Trial
- Sponsor: Sun Yat-sen University
- Enrolled: 270

## Sources

- ClinicalTrials.gov NCT07729605: https://clinicaltrials.gov/study/NCT07729605

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07729605.json